
|Podcasts|January 14, 2022
Pharmacy Focus: Psychedelic Pharmacy - Episode 3
Colonel Dallas Hack discussed the development of a novel derivative of psilocybin for the treatment of post-traumatic stress disorder
Advertisement
In this episode, Colonel Dallas Hack discussed the development of a novel derivative of psilocybin for the treatment of post-traumatic stress disorder, as well as how his own background led him to this research. In the interview, Hack said he believes a derivative could improve access as well as acceptance of the psychedelic drug.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves Ensitrelvir for Post-Exposure Prophylaxis of COVID-19 in Adolescents and Adults
2
Why Some Patients Do Not Respond to GLP-1 Therapies
3
What Pharmacists Need to Know About Retatrutide's TRIUMPH-1 Phase 3 Results
4
GIRE Combination Shows PFS Benefit in First-Line Metastatic Breast Cancer Treatment, Earning FDA Priority Review
5





































































































































